Folate-FITC
DCTPepD ID DCTPepD0036
Active Ingredients Folate-FITC
Description A conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. Folate-FITC binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, circulating anti-fluorescein antibodies may recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity.
Synonyms EC-17; Folate Fluorescein Isothiocyanate Conjugate; L-Glutamine, N2-(4-(((2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-N-(2-((((3',6'-dihydroxy-3-oxospiro(isobenzofuran-1(3H),9'-(9H)xanthen)-5-yl)amino)thioxomethyl)amino)ethyl)-; Folate-FITC
Disease Ovarian Cancer, Renal Cell Carcinoma
Classification
Amino acid and derivative Cancer targeted Conjugates
Structure Information
Molecular Formula C42H36N10O10S
Molecular Weight 872.9
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name (2S)-2-[1-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}phenyl)-N-{2-[({3',6'-dihydroxy-3-oxo-3H-spiro[2-benzofuran-1,9'-xanthene]-5-yl}carbamothioyl)amino]ethyl}formamido]-4-carbamoylbutanoic acid
InChI InChI=1S/C42H36N10O10S/c43-33(55)12-11-30(38(58)59)52(37(57)20-1-3-21(4-2-20)46-18-23-19-47-35-34(48-23)36(56)51-40(44)50-35)14-13-45-41(63)49-22-5-8-27-26(15-22)39(60)62-42(27)28-9-6-24(53)16-31(28)61-32-17-25(54)7-10-29(32)42/h1-10,15-17,19,30,46,53-54H,11-14,18H2,(H2,43,55)(H,58,59)(H2,45,49,63)(H3,44,47,50,51,56)/t30-/m0/s1
InChI_Key ZMTAPBHUSYTHBY-PMERELPUSA-N
SMILES S=C(NC1=CC2=C(C=C1)C3(C4=C(OC5=C3C=CC(O)=C5)C=C(O)C=C4)OC2=O)NCCN(C(C6=CC=C(NCC(N=C78)=CN=C8N=C(N)NC7=O)C=C6)=O)[C@@H](CCC(N)=O)C(O)=O
External Codes
PubChem CID 135564966
DrugBank Accession Number DB12559
NCI Thesaurus Code C62479
UNII V7YQ6134AE GSRS
CAS 583037-91-6
Drug approval
Drug indication
Folate Fitc has been used in trials studying the diagnostic or treatment of Ovarian Cancer, Renal Cell Carcinoma and other cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT01994369 | A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Surgery Presenting Breast Cancer | Resectable Breast Cancer | Phase 1 | Diagnostic |
| NCT02000778 | A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Intraoperative Detection of Occult Ovarian Carcinoma | Ovarian Cancer | Phase 1 | Diagnostic |
| NCT01778933 | A Pilot and Feasibility Study Of The Imaging Potential Of EC17 In Subjects Undergoing Surgery Presenting With Renal Nodules | Renal Cell Carcinoma | Phase 1 | Diagnostic |
| NCT01778920 | Intraoperative Imaging of Pulmonary Adenocarcinoma | Lung and Pleural Malignancies; Neoplasms; Nodules; Adenocarcinoma | Phase 1 | Diagnostic |
| NCT00485563 | A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma | Renal Cell Carcinoma | Phase 1 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
